<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-rchp-1l-dlbcl-thiruvengadam">
    <meta name="study:title" content="PS1914 - Multicenter real-world outcomes of frontline Pola-R-CHP in treatment naïve DLBCL">
    <meta name="study:fileName" content="Abstracts/POLA-RCHP-1L-DLBCL-THIRUVENGADAM.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Prednisone,Chemotherapy,CIT,Pola-R-CHP"> <title>PS1914: Real-World Outcomes of 1L Pola-R-CHP in DLBCL (Thiruvengadam) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1914 - Real-World Outcomes of Frontline Pola-R-CHP in DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=535)</h4>
                    <p>Treatment-naïve DLBCL. Aim: Eval real-world safety/efficacy of SOC frontline Pola-R-CHP.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pola-R-CHP)</h4>
                    <p>Standard of Care Pola-R-CHP as frontline therapy. Multicenter retrospective study (17 US centers).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Median F/U: 11 mo)</h4>
                    <p>ORR: <span class="highlight-value">92%</span>, CRR: <span class="highlight-value">80%</span><br>1-yr PFS: 81%, 1-yr OS: 91%</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>SOC Pola-R-CHP safe & effective. G≥3 Neutropenia (31%), Neuropathy (1.1%). Outcomes similar to POLARIX.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1914 - Multicenter real-world outcomes of frontline Pola-R-CHP in treatment naïve DLBCL</h1>
            <p class="abstract-sub-header">Swetha Thiruvengadam, Lu Chen, Seth Buller, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1914 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Pola-R-CHP became SOC for 1L DLBCL based on POLARIX trial (improved PFS vs R-CHOP).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the safety and efficacy of SOC frontline Pola-R-CHP outside of a clinical trial setting for treatment-naïve DLBCL.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Multicenter (17 US centers) retrospective study.</li>
                        <li>Patients: Treatment-naïve DLBCL who received Pola-R-CHP as frontline therapy (outside clinical trial). N=535.</li>
                        <li>Enrollment Period: Aug 2021 - Sep 2024.</li>
                        <li>Primary Objective: PFS of SOC Pola-R-CHP.</li>
                        <li>Secondary Objectives: Safety, ORR, CRR, OS, TTNT.</li>
                        <li>28% pts received ≥1 cycle of alternate treatment before switching to Pola-R-CHP (78% of these R-CHOP).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Real-World Study Overview</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=535)</strong>
                            <span>Treatment-Naïve DLBCL</span>
                            <span>(17 US Centers, Aug 2021 - Sep 2024)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Treatment Received</strong>
                                <span>Frontline Pola-R-CHP (SOC)</span>
                                <span class="text-xs mt-1">(28% switched after ≥1 cycle alternate Tx, mostly R-CHOP)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Primary: PFS</span>
                           <span>Secondary: Safety, ORR, CRR, OS, TTNT</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=535)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>67 (22-90)</td></tr>
                                <tr><td>Female, %</td><td>41%</td></tr>
                                <tr><td>ECOG PS ≥2, %</td><td>17%</td></tr>
                                <tr><td>Advanced Stage (III/IV), %</td><td>89%</td></tr>
                                <tr><td>>1 Extranodal Site, %</td><td>45%</td></tr>
                                <tr><td>Elevated LDH, %</td><td>63%</td></tr>
                                <tr><td>IPI Score 3-5, %</td><td>63%</td></tr>
                                <tr><td>Bulky Disease (≥7.5cm), %</td><td>33%</td></tr>
                                <tr><td>CNS Involvement, %</td><td>3.3%</td></tr>
                                <tr><td>Double Expressor, %</td><td>29%</td></tr>
                                <tr><td>Double/Triple Hit, %</td><td>3.9%</td></tr>
                                <tr><td>GCB Subtype (Hans), %</td><td>34%</td></tr>
                                <tr><td>Non-GCB Subtype (Hans), %</td><td>59%</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 11 months among survivors)</h2>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">📊</div>
                            <div class="infographic-value">92%</div>
                            <div class="infographic-label">Overall Response Rate (ORR)</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">🎯</div>
                            <div class="infographic-value">80%</div>
                            <div class="infographic-label">Complete Response Rate (CRR)</div>
                        </div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>ORR (GCB vs Non-GCB): 93% vs 92%</li>
                        <li>CRR (GCB vs Non-GCB): 77% vs 81%</li>
                        <li>1-year PFS (All Pts): 81% (95% CI: 77%-84%)
                            <ul class="list-circle list-inside ml-4">
                                <li>GCB: 78% (95% CI: 70%-84%)</li>
                                <li>Non-GCB: 82% (95% CI: 77%-86%)</li>
                            </ul>
                        </li>
                        <li>1-year OS (All Pts): 91% (95% CI: 87%-93%)
                            <ul class="list-circle list-inside ml-4">
                                <li>GCB: 91% (95% CI: 85%-95%)</li>
                                <li>Non-GCB: 91% (95% CI: 87%-94%)</li>
                            </ul>
                        </li>
                        <li>Subsequent line of treatment: 16% Pts (Median TTNT 5.8 months).</li>
                        <li>Univariate Cox: ECOG ≥2, ↑LDH, >1 extranodal sites, IPI 3-5, bulky, CNS involvement, DH/THL assoc. with inferior PFS (p<0.05). ECOG ≥2, ↑LDH, IPI 3-5 assoc. with inferior OS (p<0.05). COO not sig. assoc. with PFS/OS.</li>
                    </ul>
                     <div class="km-plot-container zoomable-image-container">
                        <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PS1914_OS_PFS_KM.jpg" alt="Overall Survival and Progression-Free Survival" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=OS/PFS+Curves+Not+Available';">
                        <p class="text-xs text-center mt-1">Overall Survival (OS) and Progression-Free Survival (PFS) (Adapted from Abstract Figure)</p>
                    </div>
                </div>
            </div>
        </div>
        
        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Safety Summary (N=535)</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2 safety-table">
                <li>Any Grade Neuropathy: 37% (Grade ≥3: 1.1%)</li>
                <li>Grade ≥3 Infection: 20%</li>
                <li>Cardiomyopathy: 3.4%</li>
                <li>Grade ≥3 Neutropenia: 31%</li>
                <li>Grade ≥3 Febrile Neutropenia: 15%</li>
                <li>Grade ≥3 Thrombocytopenia: 15%</li>
                <li>Hospitalization (TRAE-related): 31%</li>
                <li>ICU Admission (TRAE-related): 6.0%</li>
                <li>Treatment Discontinuation: 13% (Toxicity: 4.5%, Progression: 3.6%, Other: 4.7%)</li>
                <li>Treatment-Related Deaths: 1.3% (7 Pts)</li>
            </ul>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>SOC Pola-R-CHP is safe and effective for treatment-naïve DLBCL in the real world.</li>
                <li>Outcomes are similar to those found in POLARIX trial.</li>
                <li>No significant differences in efficacy based on Cell of Origin (COO).</li>
                <li>Larger sample size and longer follow-up needed for validation and subgroup efficacy.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>ADC, Antibody-Drug Conjugate; AE, Adverse Event; CHEMO, Chemotherapy; CI, Confidence Interval; CIT, Chemoimmunotherapy; CNS, Central Nervous System; COO, Cell of Origin; CRR, Complete Response Rate; DLBCL, Diffuse Large B-Cell Lymphoma; DOR, Duration of Response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; F/U, Follow-up; G, Grade; GCB, Germinal Center B-cell like; ICU, Intensive Care Unit; IPI, International Prognostic Index; LDH, Lactate Dehydrogenase; ORR, Overall Response Rate; OS, Overall Survival; PFS, Progression-Free Survival; Pola, Polatuzumab vedotin; Pola-R-CHP, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Pt(s), Patient(s); R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; SOC, Standard of Care; TRAE, Treatment-Related Adverse Event; TTNT, Time to Next Treatment.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Thiruvengadam S, Chen L, Buller S, et al. Multicenter real-world outcomes of frontline Pola-R-CHP in treatment naïve DLBCL. Abstract #PS1914 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1914 | Abstract Release: 05/14/2025 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    </body>
</html>
